Gilead Sciences, Inc. (NASDAQ:GILD) Position Lowered by Mutual Advisors LLC

Mutual Advisors LLC decreased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 54.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 23,078 shares of the biopharmaceutical company’s stock after selling 27,538 shares during the period. Mutual Advisors LLC’s holdings in Gilead Sciences were worth $2,049,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of GILD. Vanguard Group Inc. lifted its position in shares of Gilead Sciences by 2.6% during the first quarter. Vanguard Group Inc. now owns 114,732,575 shares of the biopharmaceutical company’s stock worth $8,404,161,000 after purchasing an additional 2,910,147 shares during the last quarter. Swedbank AB bought a new position in shares of Gilead Sciences during the first quarter worth about $134,489,000. International Assets Investment Management LLC lifted its position in shares of Gilead Sciences by 8,238.4% during the third quarter. International Assets Investment Management LLC now owns 1,642,504 shares of the biopharmaceutical company’s stock worth $137,708,000 after purchasing an additional 1,622,806 shares during the last quarter. Capital Research Global Investors lifted its position in shares of Gilead Sciences by 2.7% during the first quarter. Capital Research Global Investors now owns 61,246,366 shares of the biopharmaceutical company’s stock worth $4,486,296,000 after purchasing an additional 1,589,240 shares during the last quarter. Finally, Pacer Advisors Inc. lifted its holdings in Gilead Sciences by 24.7% in the second quarter. Pacer Advisors Inc. now owns 7,889,663 shares of the biopharmaceutical company’s stock worth $541,310,000 after acquiring an additional 1,564,792 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the transaction, the insider now owns 100,189 shares in the company, valued at approximately $8,398,843.87. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Gilead Sciences news, insider Johanna Mercier sold 5,490 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total value of $406,150.20. Following the transaction, the insider now owns 114,979 shares in the company, valued at approximately $8,506,146.42. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the transaction, the insider now owns 100,189 shares in the company, valued at approximately $8,398,843.87. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 36,847 shares of company stock worth $3,033,340. 0.16% of the stock is owned by insiders.

Gilead Sciences Price Performance

NASDAQ GILD opened at $88.82 on Friday. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $89.74. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.14 and a quick ratio of 0.95. The firm has a market capitalization of $110.66 billion, a PE ratio of 246.72, a P/E/G ratio of 3.07 and a beta of 0.18. The company’s 50 day simple moving average is $83.54 and its 200 day simple moving average is $73.97.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating analysts’ consensus estimates of $1.61 by $0.40. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The business had revenue of $6.95 billion for the quarter, compared to analyst estimates of $6.64 billion. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post 3.76 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Piper Sandler reissued an “overweight” rating and issued a $95.00 target price on shares of Gilead Sciences in a report on Wednesday, September 11th. Royal Bank of Canada reissued a “sector perform” rating and issued a $75.00 target price on shares of Gilead Sciences in a report on Tuesday. Leerink Partnrs raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Monday, October 21st. Cantor Fitzgerald reissued a “neutral” rating and issued a $70.00 target price on shares of Gilead Sciences in a report on Monday, September 16th. Finally, Leerink Partners upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and raised their price target for the company from $74.00 to $96.00 in a research note on Monday, October 21st. Ten research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and an average target price of $86.85.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.